BURNABY, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation ...
BURNABY, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation ...
VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunomodulation ...
Qu Biologics Inc. has reported data showing that its Qbeco site specific immunomodulator (SSI) improved fatty liver disease and its deleterious consequences in a mouse model of preexisting obesity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results